title: Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy.
abstract: Gc protein-derived macrophage-activating factor (GcMAF) occurs naturally in the human body. It has various functions, such as macrophage activation and antitumor activities. Recently, immunotherapy has become an attractive new strategy in the treatment of cancer. GcMAF-based immunotherapy can be combined with many other therapies. Sonodynamic therapy (SDT) using low-intensity ultrasound is a novel therapeutic modality. Ultrasound has been demonstrated to activate a number of sonosensitive agents allowing for the possibility of non-invasive targeted treatment for both superficial and deep-seated tumors. The current case study demonstrates that GcMAF and SDT can be used in combination with conventional therapies in patients with metastatic cancer, especially where treatment options are limited due to factors such as toxicity. This case study also suggests a new concept of cancer treatment using local destruction of cancer tissue, in this case conducted with SDT, to be used in combination with GcMAF immunotherapy as a systemic treatment.
authors: Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan Kobe Saisei Mirai Clinic, Kobe, Japan Inui Immunotherapy Clinic, Osaka, Japan Tokyo Saisei Mirai Clinic, Tokyo, Japan contact@saisei-mirai.or.jp.
authors: Toshio
authors: T
authors: Inui
authors: Kobe Saisei Mirai Clinic, Kobe, Japan.
authors: Kaori
authors: K
authors: Makita
authors: Tokyo Saisei Mirai Clinic, Tokyo, Japan.
authors: Hirona
authors: H
authors: Miura
authors: Tokyo Saisei Mirai Clinic, Tokyo, Japan.
authors: Akiko
authors: A
authors: Matsuda
authors: Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan.
authors: Daisuke
authors: D
authors: Kuchiike
authors: Saisei Mirai Cell Processing Center, Osaka, Japan.
authors: Kentaro
authors: K
authors: Kubo
authors: Inui Immunotherapy Clinic, Osaka, Japan.
authors: Martin
authors: M
authors: Mette
authors: Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan.
authors: Yoshihiro
authors: Y
authors: Uto
authors: Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe, Japan Frontier Institute for Biomolecular Engineering Research (FIBER), Konan University, Kobe, Japan.
authors: Takahito
authors: T
authors: Nishikata
authors: Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan.
authors: Hitoshi
authors: H
authors: Hori
authors: Division of Food and Drug Evaluation Science, Department of Community Medicine and Social Healthcare Science, Graduate School of Medicine, Kobe University, Kobe, Japan.
authors: Norihiro
authors: N
authors: Sakamoto
mesh_terms: D000730:Androstadienes / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016215:Macrophage-Activating Factors / Q000627:therapeutic use*; D008875:Middle Aged; D014464:Ultrasonic Therapy / Q000379:methods*; D014809:Vitamin D-Binding Protein / Q000627:therapeutic use*
chemical_list: D000730:Androstadienes; D016215:Macrophage-Activating Factors; D014809:Vitamin D-Binding Protein; C101908:vitamin D-binding protein-macrophage activating factor; C056516:exemestane
keywords: GeMAF; Immunotherapy; SDT; breast cancer; case report; macrophage; sonodynamic therapy